CAMBRIDGE, England–(BUSINESS WIRE)–Shift Bioscience (Shift), a biotechnology company uncovering the biology of cell rejuvenation to develop new therapies for age driven diseases, today announced the publication of new research in Nature Biotechnology describing an improved calibration framework for deep learning-based genetic perturbation models1. Shift will use the framework to support large-scale in vitro and in silico screens to identify novel inhibition targets with potential application